GlassScriptPhysician profile
Eugene Kim Soh
NPI 1588672000
$10,745.99
in general payments reported to CMS, 2019-2025
38 companies · $2,073 in 2025
The $2,073 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,256 · 2020: $306 · 2021: $1,648 · 2022: $1,644 · 2023: $1,605 · 2024: $1,213 · 2025: $2,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,891.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $1,860.37 | 2019-2022 | |
| Boston Scientific Corporation | $1,277.47 | 2019-2025 | Rotapro, Watchman Access System, Synergy |
| Novartis Pharmaceuticals Corporation | $790.28 | 2019-2025 | |
| Abbott Laboratories | $681.80 | 2019-2024 | Aveir, Jot Dx, Mitraclip |
| E.R. Squibb & Sons, L.L.C. | $579.14 | 2021-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $576.65 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $460.65 | 2019-2025 | Lifevest |
| Scpharmaceuticals INC. | $411.97 | 2024-2025 | |
| Pfizer INC. | $393.10 | 2019-2025 | |
| Abiomed | $360.20 | 2019-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $311.63 | 2019-2025 | Farxiga, Brilinta |
| Heartflow, INC. | $268.78 | 2024-2025 | |
| Novo Nordisk INC | $267.71 | 2023-2025 | Ozempic |
| Cvrx, INC. | $241.42 | 2024-2025 | Barostim Neo System |
| Edwards Lifesciences Corporation | $224.95 | 2019-2025 | Sapien 3 Ultra Resilia |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.06 | 2019-2025 | Jardiance |
| Medtronic, INC. | $166.77 | 2025 | Linq II |
| Bridgebio Pharma, INC. | $165.67 | 2025 | Attruby |
| Amgen INC. | $162.69 | 2019-2025 | Repatha, Repatha |
| Chiesi USA, INC. | $154.49 | 2019-2025 | Kengreal |
| Amarin Pharma, INC. | $149.20 | 2019-2022 | |
| Zoll Respicardia, INC. | $136.38 | 2021 | |
| Atricure, INC. | $134.46 | 2022 | |
| Merck Sharp & Dohme LLC | $126.49 | 2023-2025 | Verquvo, Capvaxive |
| Lilly USA, LLC | $124.51 | 2025 | |
| Esperion Therapeutics, INC. | $118.16 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $85.79 | 2019-2025 | Uptravi, Opsumit |
| Portola Pharmaceuticals, LLC | $64.53 | 2019 | |
| Philips North America LLC | $49.62 | 2020 | |
| Kestra Medical Technology Services, INC. | $42.42 | 2025 | Assure Wcd |
| Medicomp INC | $29.11 | 2023 | Telepatch Cardiac Monitor |
| Recor Medical INC | $28.00 | 2025 | Paradise Ultrasound Renal Denervation System |
| Viatris Specialty LLC | $24.87 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $22.90 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.64 | 2023 | |
| Cardiofocus, INC. | $17.70 | 2019 | |
| Shockwave Medical, INC | $13.13 | 2022 | |
| Penumbra, INC. | $12.28 | 2023 | Indigo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Soh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.